The clinical profile of NMOSD in Australia and New Zealand.
Aquaporin
Autoimmune disease
Clinical features
Multiple sclerosis
Neuromyelitis optica
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
05
11
2019
accepted:
18
01
2020
revised:
12
01
2020
pubmed:
2
2
2020
medline:
9
2
2021
entrez:
2
2
2020
Statut:
ppublish
Résumé
Neuromyelitis optica spectrum disorders (NMOSD) are an inflammation of the central nervous system associated with autoantibodies to aquaporin-4. We have undertaken a clinic-based survey of NMOSD in the Australia and New Zealand populations with the aim of characterising the clinical features and establishing the value of recently revised diagnostic criteria. Cases of possible NMOSD and age and sex-matched controls with multiple sclerosis (MS) were referred from centres across Australia and New Zealand. Cases were classified as NMOSD if they met the 2015 IPND criteria and remained as suspected NMOSD if they did not. Clinical and paraclinical data were compared across the three groups. NMOSD was confirmed in 75 cases and 89 had suspected NMOSD. There were 101 controls with MS. Age at onset, relapse rates and EDSS scores were significantly higher in NMOSD than in MS. Lesions and symptoms referable to the optic nerve were more common in NMOSD whereas brainstem, cerebellar and cerebral lesions were more common in MS. Longitudinally extensive spinal cord lesions were seen in 48/71 (68%) of cases with NMOSD. Elevations of CSF, white cell count and protein were more common in NMOSD. We have confirmed a clinical pattern of NMOSD that has been seen in several geographical regions. We have demonstrated the clinical utility of the current diagnostic criteria. Distinct patterns of disease are evident in NMOSD and MS, but there remains a large number of patients with NMOSD-like features who do not meet the current diagnostic criteria for NMOSD and remain a diagnostic challenge.
Identifiants
pubmed: 32006158
doi: 10.1007/s00415-020-09716-4
pii: 10.1007/s00415-020-09716-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1431-1443Subventions
Organisme : Multiple Sclerosis Research Australia
ID : 11-038
Organisme : Griffith Health Institute, Griffith University
ID : n/a
Organisme : NIHR Oxford Biomedical Research Centre
ID : n/a
Références
Pittock SJ, Lucchinetti CF (2016) Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci 1366(1):20–39. https://doi.org/10.1111/nyas.12794
doi: 10.1111/nyas.12794
pubmed: 26096370
Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kumpfel T, Neuromyelitis Optica Study G (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1–16. https://doi.org/10.1007/s00415-013-7169-7
doi: 10.1007/s00415-013-7169-7
pubmed: 24272588
Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67(8):1016–1017. https://doi.org/10.1001/archneurol.2010.188
doi: 10.1001/archneurol.2010.188
pubmed: 20697055
Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, Tubridy N, Boggild M (2012) Does natalizumab therapy worsen neuromyelitis optica? Neurology 79(10):1065–1066. https://doi.org/10.1212/WNL.0b013e31826845fe
doi: 10.1212/WNL.0b013e31826845fe
pubmed: 22914835
Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, Tsumiyama I, von Rosenstiel P, Zhang-Auberson L, Saida T (2014) Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol 14:21. https://doi.org/10.1186/1471-2377-14-21
doi: 10.1186/1471-2377-14-21
pubmed: 24475777
pmcid: 3911956
Kowarik MC, Hoshi M, Hemmer B, Berthele A (2016) Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab. Neurol Neuroimmunol Neuroinflamm 3(2):e208. https://doi.org/10.1212/NXI.0000000000000208
doi: 10.1212/NXI.0000000000000208
pubmed: 26913290
pmcid: 4751152
Huang W, Wang L, Zhang B, Zhou L, Zhang T, Quan C (2019) Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis. Mult Scler Relat Disord 35:246–252. https://doi.org/10.1016/j.msard.2019.08.009
doi: 10.1016/j.msard.2019.08.009
pubmed: 31425902
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E, Investigators NMs (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. https://doi.org/10.1016/S0140-6736(19)31817-3
doi: 10.1016/S0140-6736(19)31817-3
pubmed: 31690442
Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T, Yamamura T (2014) Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82(15):1302–1306. https://doi.org/10.1212/WNL.0000000000000317
doi: 10.1212/WNL.0000000000000317
pubmed: 24634453
pmcid: 4001188
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381(7):614–625. https://doi.org/10.1056/NEJMoa1900866
doi: 10.1056/NEJMoa1900866
pubmed: 31050279
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMOD (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189. https://doi.org/10.1212/WNL.0000000000001729
doi: 10.1212/WNL.0000000000001729
pubmed: 26092914
pmcid: 26092914
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485–1489. https://doi.org/10.1212/01.wnl.0000216139.44259.74
doi: 10.1212/01.wnl.0000216139.44259.74
pubmed: 16717206
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. https://doi.org/10.1002/ana.22366
doi: 10.1002/ana.22366
pubmed: 21387374
pmcid: 21387374
Prain K, Woodhall M, Vincent A, Ramanathan S, Barnett MH, Bundell CS, Parratt JDE, Silvestrini RA, Bukhari W, Australian T, New Zealand NMO, Collaboration BF, Waters P, Broadley SA (2019) AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD. Front Neurol 10:1028
doi: 10.3389/fneur.2019.01028
Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG (2007) A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 68(8):603–605. https://doi.org/10.1212/01.wnl.0000254502.87233.9a
doi: 10.1212/01.wnl.0000254502.87233.9a
pubmed: 17310032
Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, Eisen KA, Purves SJ, Low MD, Brandejs V (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38(2):180–185
doi: 10.1212/WNL.38.2.180
Yang CS, Zhang DQ, Wang JH, Jin WN, Li MS, Liu J, Zhang CJ, Li T, Shi FD, Yang L (2014) Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China. CNS Neurosci Ther 20(1):32–39. https://doi.org/10.1111/cns.12156
doi: 10.1111/cns.12156
pubmed: 23890015
Srikajon J, Siritho S, Ngamsombat C, Prayoonwiwat N, Chirapapaisan N, Siriraj Neuroimmunology Research G (2018) Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis. Mult Scler J Exp Transl Clin 4(3):2055217318791196. https://doi.org/10.1177/2055217318791196
doi: 10.1177/2055217318791196
pubmed: 30116549
pmcid: 6088491
Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zephir H, Moder K, Weinshenker BG (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65(1):78–83. https://doi.org/10.1001/archneurol.2007.17
doi: 10.1001/archneurol.2007.17
pubmed: 18195142
Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, Franciotta D, Rommer P, Mader S, Kleiter I, Reindl M, Akman-Demir G, Seifert-Held T, Kristoferitsch W, Melms A, Wandinger KP, Wildemann B (2011) Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 17(9):1067–1073. https://doi.org/10.1177/1352458511403958
doi: 10.1177/1352458511403958
pubmed: 21543553
Shahmohammadi S, Doosti R, Shahmohammadi A, Mohammadianinejad SE, Sahraian MA, Azimi AR, Harirchian MH, Asgari N, Naser Moghadasi A (2019) Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review. Mult Scler Relat Disord 27:350–363. https://doi.org/10.1016/j.msard.2018.11.008
doi: 10.1016/j.msard.2018.11.008
pubmed: 30476871
Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA (2017) Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2016-314839
doi: 10.1136/jnnp-2016-314839
pubmed: 28550069
Adoni T, Lino AM, da Gama PD, Apostolos-Pereira SL, Marchiori PE, Kok F, Callegaro D (2010) Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Mult Scler 16(1):81–86. https://doi.org/10.1177/1352458509353651
doi: 10.1177/1352458509353651
pubmed: 19995833
Eskandarieh S, Nedjat S, Azimi AR, Moghadasi AN, Sahraian MA (2017) Neuromyelitis optica spectrum disorders in Iran. Mult Scler Relat Disord 18:209–212. https://doi.org/10.1016/j.msard.2017.10.007
doi: 10.1016/j.msard.2017.10.007
pubmed: 29141812
Houzen H, Kondo K, Niino M, Horiuchi K, Takahashi T, Nakashima I, Tanaka K (2017) Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology 89(19):1995–2001. https://doi.org/10.1212/WNL.0000000000004611
doi: 10.1212/WNL.0000000000004611
pubmed: 28986408
Hyun JW, Jeong IH, Joung A, Kim SH, Kim HJ (2016) Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology 86(19):1772–1779. https://doi.org/10.1212/WNL.0000000000002655
doi: 10.1212/WNL.0000000000002655
pubmed: 27164713
Pandit L, Kundapur R (2014) Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 20(12):1651–1653. https://doi.org/10.1177/1352458514521503
doi: 10.1177/1352458514521503
pubmed: 24493471
Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, Das K, Boggild M (2013) The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 260(8):2134–2137. https://doi.org/10.1007/s00415-013-6926-y
doi: 10.1007/s00415-013-6926-y
pubmed: 23689970
Chen H, Liu SM, Zhang XX, Liu YO, Li SZ, Liu Z, Dong HQ (2016) Clinical features of patients with multiple sclerosis and neuromyelitis optica spectrum disorders. Chin Med J (Engl) 129(17):2079–2084. https://doi.org/10.4103/0366-6999.189046
doi: 10.4103/0366-6999.189046
Jurynczyk M, Craner M, Palace J (2015) Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 86(1):20–25. https://doi.org/10.1136/jnnp-2014-308984
doi: 10.1136/jnnp-2014-308984
pubmed: 25248365
Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Munch C, Winkelmann A, Zettl UU, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflamm 9:14. https://doi.org/10.1186/1742-2094-9-14
doi: 10.1186/1742-2094-9-14
Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Yoshiki T, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ (2018) Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology 91(17):e1642–e1651. https://doi.org/10.1212/WNL.0000000000006392
doi: 10.1212/WNL.0000000000006392
pubmed: 30258024
pmcid: 6205685